ABSTRACT
IARC MONOGRAPH 4 1974 ADMINISTRATION OF 1,4-BUTANEDIOL DIMETHANESULPHONATE TO THE MOUSE BY INTRAPERITONEAL INJECTION AND TO THERA T BY ORAL ADMINISTRATION DID NOT SIGNIFICANTLY INCREASE THE INCIDENCE OF TUMORS. INTRA VENOUS ADMINISTRATION IN THE MOUSE SIGNIFICANTLY INCREASED THE INCIDENCE OF THYMIC LYMPHOMAS AND OVARIAN TUMORS. ALTHOUGH THERE IS EVIDENCETHATHISTOLOGICALANDCYTOLOGICALCHANGESARE ASSOCIATED WITH MYLERAN THERAPY, THERE IS NO FIRM EVIDENCE OF AN INCREASED CANCER RISK AMONG THOSE TREATED.
